Drugs and Rhabdomyolysis: from Liver to kidney.

Drugs and Rhabdomyolysis: from Liver to kidney. Curr Vasc Pharmacol. 2015 Jan 30; Authors: Barbano B, Sardo L, Gasperini ML, Gigante A, Liberatori M, Giraldi G DL, Di Mario F, Dorelli B, Amoroso A, Cianci R Abstract Rhabdomyolysis is a syndrome due to a damage of skeletal muscle and the leakage of intracellular contents into the extracellular fluid and the circulation. Several causes may induce rhabdomyolysis and the major one is the crush syndrome. Most cases of non-traumatic rhabdomyolysis are related to drugs. Many molecules are subject to hepatic metabolism and the concomitant use of drugs, as statins, with other medications acting as substrates of the same isoenzymes can interact and increase the risk of myopathy. Subclinical rise of creatine kinase may be expression of rhabdomyolysis that can range even to medical emergency such as acute kidney injury (AKI), compartment syndrome, cardiac dysrhythmias and disseminated intravascular coagulopathy. The main pathophysiological mechanisms of myoglobinuric-related AKI are renal vasoconstriction, formation of intraluminal casts and direct cytotoxicity promoted by heme-protein. The aim of this review is to analyze the pathophysiology of myolysis, the causes of rhabdomyolysis and especially the link between the liver and the kidney, which can represent the connecting element for the development of the syndrome. PMID: 25633322 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research

Related Links:

Background and Aims: Higher plasma statin concentrations increase the concentration of statin in muscle, thereby increasing the risk of statin related myotoxicity (SRM), including myopathy and rhabdomyolysis. OATP1B1, encoded by the SLCO1B1 gene, mediates hepatic uptake from portal blood. The association of rs4149056 single-nucleotide polymorphism in SLCO1B1 with simvastatin-induced myopathy is well-established but it is less clear whether this genetic variant is a useful predictor of plasama concentrations and risk of SRM with atorvastatin, the most widely prescribed high-potency statin.
Source: Atherosclerosis - Category: Cardiology Authors: Tags: Posters 26 - 29 May, 2019 Source Type: research
We report the case of a 46-years-old man with long-term asymptomatic hyperuricemia who started taking colchicine (0.5 mg/day) and allopurinol (100 mg/d) for normalization of biochemical values. After the third week of starting treatment, acute weakness was present; and by the fifth week, profound weakness in lower extremities and tenderness and cramps on thighs and calves with inability to climb stairs were also observed. Biochemical evaluation showed elevated muscle enzymes (creatinine kinase [CK] raised to five-folds its normal value) and electromyographic features were consistent with myopathy (at rest, fi...
Source: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders - Category: Orthopaedics Tags: Clin Med Insights Arthritis Musculoskelet Disord Source Type: research
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Diagnostic Dilemma Source Type: research
A 73-year-old gentleman presented with progressive weakness over the course of a few months, more prominent in the lower extremities. He denied myalgia, seizures, immobilization, fever, or viral-like illness. His comorbidities were significant for coronary artery disease, hypothyroidism, and hyperlipidemia. Medications included metoprolol, aspirin, thyroxine, and atorvastatin, which was started 4 years prior to presentation. Patient denied any alcohol consumption or illicit drug use.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Diagnostic Dilemma Source Type: research
This article is protected by copyright. All rights reserved. PMID: 31220337 [PubMed - as supplied by publisher]
Source: Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Tags: Clin Pharmacol Ther Source Type: research
Studies have demonstrated that statins reduce cardiovascular risk in men and women, but the effectiveness of statins among low-risk women continues to be contentious. One reason is that the number of women enrolled in statin trials has been small relative to men, limiting statistical inferences. Also, for any given age women have a lower absolute risk of cardiovascular disease when compared to men. When absolute benefit is low, the risk of adverse effects becomes more important. Myopathy and rhabdomyolysis are rare but established side-effects of statin therapy, and concern is growing that statins could increase the risk o...
Source: Maturitas - Category: Primary Care Authors: Tags: INV24 Source Type: research
Conclusions: Muscle damage induced by interaction between FA and statin is a potentially life-threatening complication, leading to contraindication of this association in France. This is to be reminded especially because FA is about to get FDA approval and should soon be available in the United States.
Source: American Journal of Therapeutics - Category: Drugs & Pharmacology Tags: Systematic Reviews Source Type: research
Authors: Pennisi M, Di Bartolo G, Malaguarnera G, Bella R, Lanza G, Malaguarnera M Abstract Introduction: Statin-associated muscle symptoms are common side effects of statin therapy. These symptoms include myopathy, myalgia, and rhabdomyolysis. Vitamin D has been associated with musculoskeletal health; thus, its deficiency may produce detrimental effects in this tissue. Indeed, one symptom of vitamin D deficiency is myalgia, and the normalization of low vitamin D levels can relieve it. Patients and Methods: This cross-sectional study examined 1210 statin-treated patients to assess vitamin D status. These patien...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Publication date: Available online 12 March 2019Source: Pharmacological ResearchAuthor(s): Jamal Bouitbir, Gerda M. Sanvee, Miljenko V. Panajatovic, François Singh, Stephan KrähenbühlAbstractStatins lower the serum low-density lipoprotein cholesterol and prevent cardiovascular events by inhibiting 3-hydroxy-3-methyl-glutaryl-CoA reductase. Although the safety of statins is documented, many patients ingesting statins may suffer from skeletal muscle-associated symptoms (SAMS). Importantly, SAMS are a common reason for stopping the treatment with statins. Statin-associated muscular symptoms include fatigue, w...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
In this study, a rhabdomyolysis mouse model was established by coadministration of the clinically using statin and fibrate. This mouse model may be useful to identify drugs that have high risk for rhabdomyolysis. PMID: 30853469 [PubMed - as supplied by publisher]
Source: Toxicology Letters - Category: Toxicology Authors: Tags: Toxicol Lett Source Type: research
More News: Cholesterol | Drugs & Pharmacology | Emergency Medicine | Liver | Rhabdomyolysis | Statin Therapy | Urology & Nephrology